Wide Ranks

ENGNW

enGene Holdings Inc. Warrants

1.45

Top Statistics
Market Cap 0.0000 Forward PE 0.0000 Revenue Growth 0.00 %
Current Ratio 19.52 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 257 M Total Cash Per Share 5.83 Total Debt 24 M
Total Debt To Equity 10.79 Current Ratio 19.52 Book Value Per Share 5.21
All Measures
Message Board Id finmb_9516520 Return On Equity -1.23 City Saint-Laurent
Uuid 40bdb60c-7978-3e5f-a34f-a5ca8ec5f13f Previous Close 1.45 Book Value 5.21
Beta -0.7570 Total Debt 24 M Volume 13703
Price To Book 0.2784 Fifty Two Week Low 1.45 Total Cash Per Share 5.83
Max Age 86400 Sand P52 Week Change 0.3133 Net Income To Common -123436000
Trailing Peg Ratio None Total Cash 257 M Trailing PE 0.0000
Regular Market Previous Close 1.45 Target Low Price 0.0000 Gmt Off Set Milliseconds -18000000
Open 1.50 Free Cashflow -23581124 State QC
Dividend Yield 0.00 % Return On Assets -0.2207 Time Zone Short Name EST
Day Low 1.45 Address1 7171 Rue Frederick Banting Target High Price 0.0000
Price Hint 4 Website https://www.engene.com Forward Eps 0.0000
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 1916.50 %
Is_sp_500 False Regular Market Day High 1.45 Profit Margins 0.00 %
Debt To Equity 10.79 Fifty Two Week High 1.45 Day High 1.45
Regular Market Open 1.50 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Operating Cashflow -35489000 Currency USD
Time Zone Full Name America/New_York Is_nasdaq_100 False Market Cap 0.0000
Zip H4S 1Z9 Quote Type EQUITY Industry Biotechnology
Long Name enGene Holdings Inc. Regular Market Day Low 1.45 Current Price 1.45
Financial Currency USD Current Ratio 19.52 Industry Disp Biotechnology
Country Canada Float Shares 16 M Forward PE 0.0000
Regular Market Volume 13703 Ebitda -54995000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.

Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.

The company was founded in 2023 and is based in Saint-Laurent, Canada.